0 Comments
0 Shares
97 Views
0 Reviews
Search
Discover new people, create new connections and make new friends
-
Please log in to like, share and comment!
-
Bevacizumab Biosimilar Market OverviewThe Bevacizumab Biosimilar Market was valued at $2.18 billion in 2024 and is projected to reach $5 billion by 2035, growing at a CAGR of 7.8%. Bevacizumab biosimilars offer cost-effective alternatives to the reference biologic Avastin, treating multiple cancers by inhibiting vascular endothelial growth factor (VEGF). The market encompasses various formulation types including intravenous and...0 Comments 0 Shares 12 Views 0 Reviews